Our Biofunctional Nanomaterials group research the design and development of self-assembling nanostructures/platforms for biomedical applications based on the building blocks of life, namely peptide and their unnatural variants (peptide-mimetics).
These structures have the ability to form nanofibrous hydrogels or nanotubular structures with high surface to volume ratios in the presence of specific physiological stimuli (e.g. pH, temperature, enzymes). They have huge potential within the fields of drug delivery and biomaterials with the group’s focus primarily on the development of antimicrobial and anticancer technologies, sustained release drug delivery systems (injectable implants) and molecules with the ability to transverse the biological barriers (e.g. blood-brain barrier, outer membrane of Gram-negative bacteria).
Our most recent work relates to the development of self-assembling peptide-based hydrogel materials for use against infection and as long releasing implants for diseases with medication adherence issues (e.g. HIV/AIDs).
Harnessing a “bottom-up” approach, variation of the primary amino acid sequence of peptides allows structures to spontaneously assemble into ordered nanostructures upon exposure to varying environmental factors/stimuli. The peptide backbone provides a unique primer for tailoring biocompatibility, biodegradability and functionality.
We have interest in developing these technologies with the ultimate goal of translating them into healthcare products for patient benefit, working closely with our academic partners, funding agencies, charities, industry, clinicians and the public.
An in situ forming, enzyme responsive, long-acting peptide hydrogel drug delivery implants for HIV/AIDs (January 2023).
Research Webinar: Spring 2022.
Our peptide hydrogel research wins Controlled Release Society’s 2020 People’s Choice Award
06 July, 2020
We are excited to hear our research on the use of peptide hydrogels for HIV/AIDs drug delivery won the overall CRS People’s Choice Award at the recent CRS virtual meeting. The presentation, as well as our other work, is available to conference participants by clicking the relevant title below. Poster: Poster number 63. Peptide-like […]
Latest hydrogel work published in Chemical Communications
17 June, 2020
Our latest collaborative work on entitled “Tuning the antimicrobial activity of low molecular weight hydrogels using dopamine autoxidation,” has been accepted within Chemical Communications. This work was led by Emily Cross and represents a collaboration with Prof Dave Adams’ Group at the School of Chemistry University of Glasgow and is freely available here. Thanks again […]
Latest publication: Pharmaceutical formulation and characterization of dipeptide nanotubes for drug delivery applications
03 June, 2020
Our latest paper has been published in the journal Macromolecular Bioscience focusing on formulating peptide nanotubes using mild techniques to improve potential for pharmaceutical upscale. Paper can be accessed here: https://doi.org/10.1002/mabi.202000115 Abstract Peptide nanotubes are promising materials for a variety of biomedical applications with ultrashort (≤7 amino acids) forms providing particular promise for clinical translation. […]
Group receive major funding from EPSRC to develop peptide-like hydrogels for combined HIV-contraceptive therapy
03 September, 2019
We are excited to announce support from the Engineering and Physical Sciences Research Council (EPSRC) to develop of peptide-like hydrogels for use as a long-acting injectable delivery platform for combined HIV-contraceptive drug delivery. Total support (£766,542) will allow further development of our peptide-mimetic platforms in a key healthcare area in collaboration with our co-investigators at […]
Our book, Hydrogels: Design, synthesis & application in drug delivery & regenerative medicine, available now!
01 October, 2018
If you are interested in knowing more about the potential applications of our hydrogels, remember to check out our recent book “Hydrogels: Design, synthesis & application in drug delivery & regenerative medicine,” co-edited alongside Dr Raj Thakur and Prof Ryan Donnelly. Thanks to all those who contributed.
PhD positions available within our group: 7th January 2019 deadline
07 December, 2018
A number of PhD positions are available within the group. Funding will be allocated to successful applicants rather, than project. Successful applicant will receive tuition fees(UK/EU) paid and a stipend (for UK residents only). Closing date for all applications is 7th January 2019 with interviews being scheduled for February 2019. Dr Garry Laverty (First […]
Research Group receive Innovate UK ICURe SETsquared Award
24 February, 2021
We are delighted to be currently taking part in the UKRI Innovate UK ICURe SETsquared Cohort 32 (32-08 / 520268133: £30,000). This programme is allowing us to market validate our peptide hydrogel technology in a variety of applications both within drug delivery and the wider commercial landscape. Our Research Associate Simon Porter is currently undertaking these […]
Funding for Medical Research Council: Confidence in Concept Project
25 April, 2020
We are happy to announce our group has received funding as part of the MRC CiC programme (£67,867) to study the use of antiretroviral drugs in HIV/AIDs prevention alongside our industry partners. Funding will enable a Research Fellow to work within our group on this project for one year. We should hopefully be in a […]